Novel Gemini vitamin D3 analogs: Large structure/function analysis and ability to induce antimicrobial peptide

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 207-217

  Okamoto, Ryoko ^a   Gery, Sigal ^a   Kuwayama, Yoshio ^a   Borregaard, Niels ^b   Ho, Quoc ^a   Alvarez, Rocio ^a   Akagi, Tadayuki ^a   Liu, George Y ^a   Uskokovic, Milan R ^c   Koeffler, H Phillip ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Copenhagen   (Denmark)

^c RUTGERS UNIVERSITY   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

antitumor; deuterated Gemini vitamin D3; human cathelicidin antimicrobial peptide; vitamin D3

Indexed keywords

BXL 01 0077; BXL 01 0078; BXL 01 0079; BXL 01 0082; BXL 01 0083; BXL 01 0084; BXL 01 0085; BXL 01 0086; BXL 01 0088; BXL 01 0089; BXL 01 0091; BXL 01 0092; BXL 01 0093; BXL 01 0094; BXL 01 0095; BXL 01 0098; BXL 01 0099; BXL 01 0100; BXL 01 0101; BXL 01 0102; BXL 01 0103; BXL 01 0108; BXL 01 0109; BXL 01 0110; BXL 01 0114; BXL 01 0115; BXL 01 126; CALCITRIOL; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAMP GENE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; DOSE RESPONSE; GENE; GENE EXPRESSION; HYPERCALCEMIA; IN VITRO STUDY; LEUKEMIA CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; VITAMIN D RESPONSIVE ELEMENT;

ANTITUMOR; DEUTERATED GEMINI VITAMIN D3; HUMAN CATHELICIDIN ANTIMICROBIAL PEPTIDE; VITAMIN D3;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CATHELICIDINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLECALCIFEROL; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; MICE; REAL-TIME POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885952709     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28328     Document Type: Article

References (41)

1. Norman AW, Bouillon R,. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) 2010; 235: 1034-45.
2. Krishnan AV, Trump DL, Johnson CS, et al. The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 2012; 38: 161-78.
3. Reichel H, Koeffler HP, Norman AW,. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320: 980-91.
4. Mangelsdorf D, Koeffler H, Donaldson C, et al. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98: 391-8.
5. Koeffler H, Hirji K, Itri L,. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399-407.
6. Koeffler H, Amatruda T, Ikekawa N, et al. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res 1984; 44: 5624-8.
7. Spina C, Tangpricha V, Yao M, et al. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol 2005; 97: 111-20.
8. Norman AW, Zhou JY, Henry HL, et al. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res 1990; 50: 6857-64.
9. Saito T, Okamoto R, Haritunians T, et al. Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008; 112: 151-6.
10. Lee HJ, So JY, DeCastro A, et al. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 2010; 121: 408-12.
11. Norman AW,. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-8.
12. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25- dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-12.
13. Gombart A, Borregaard N, Koeffler H,. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067-77.
14. Holick MF,. Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol 2011; 7: 73-5.
15. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-43.
16. Hancock RE, Lehrer R,. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16: 82-8.
17. Hancock RE, Patrzykat A,. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2: 79-83.
18. Sørensen O, Arnljots K, Cowland JB, et al. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997; 90: 2796-803.
19. Shultz LD, Ishikawa F, Greiner DL,. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-30.
20. Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-7.
21. Pahl HL, Scheibe RJ, Zhang DE, et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993; 268, 5014-20.
22. Tomlins SA, Rhodes DR, Perner S, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
23. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9.
24. Papapoulos SE, Clemens TL, Sandler LM, et al. The effect of renal function on changes in circulating concentrations of 1,25- dihydroxycholecalciferol after an oral dose. Clin Sci (Lond) 1982; 62: 427-9.
25. O'Kelly J, Uskokovic M, Lemp N, et al. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol 2006; 100: 107-16.
26. 3: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011; 25: 543-59.
27. Okamoto R, Delansorne R, Wakimoto N, et al. Inecalcitol, an analog of 1α,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 2012; 130: 2464-73.
28. Kumar-Sinha C, Tomlins S, Chinnaiyan A,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
29. Zhao XY, Peehl DM, Navone NM, et al. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000; 141: 2548-56.
30. Cai C, Hsieh CL, Omwancha J, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007; 21: 1835-46.
31. Baena E, Shao Z, Linn DE, et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013; 27: 683-98.
32. Swami S, Krishnan AV, Feldman D,. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol 2011; 347: 61-9.
33. Skowronski RJ, Peehl DM, Feldman D,. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.
34. Williams CJB,. Cod liver oil in phthisis. Lond J Med 1849; 1: 1-18.
35. Martineau A, Honecker F, Wilkinson R, et al. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007; 103: 793-8.
36. Najada AS, Habashneh MS, Khader M,. The frequency of nutritional rickets among hospitalized infants and its relation to respiratory diseases. J Trop Pediatr 2004; 50: 364-8.
37. Ginde AA, Mansbach JM, Camargo CA,. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169: 384-90.
38. Jeng L, Yamshchikov AV, Judd SE, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28.
39. Travis SM, Anderson NN, Forsyth WR, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68: 2748-55.
40. Nagaoka I, Hirota S, Niyonsaba F, et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001; 167: 3329-38.
41. Gombart A, O'Kelly J, Saito T, et al. Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 2007; 103: 552-7.